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ABSTRACT  
Background 
BRCA-carrier identification offers opportunities for early-diagnoses, targeted treatment and cancer 
prevention. We evaluate BRCA-carrier detection rates in General and Ashkenazi-Jewish(AJ) 
populations across Greater-London and estimate time-to-detection of all identifiable BRCA-carriers.   
Methods 
BRCA-carrier data from 1993-2014 were obtained from NHS genetic-laboratories and compared with 
modelled predictions of BRCA-prevalence from published literature and geographical data from UK 
Office-for-National-Statistics. Proportion of BRCA-carriers identified was estimated. Prediction-
models were developed to fit BRCA-detection rate data. BRCA-carrier identification rates were 
evaluated for an “Angelina-Jolie effect”. Maps for four Greater-London regions were constructed 
and their relative BRCA-detection rates compared. Models developed were used to predict future 
time-to-identify all detectable BRCA-carriers in AJ-&-general populations.  
Results 
Till 2014, only 2.6%(3072/111742 estimated) general-population and 10.9%(548/4985 estimated) AJ-
population BRCA-carriers have been identified in 16,696,608(AJ=190,997) Greater-London 
population. 57% general-population and 54% AJ mutations were identified through cascade-testing. 
Current detection rates mirror linear-fit rather than parabolic-model and will not identify all BRCA-
carriers. Addition of unselected ovarian/triple-negative breast cancer testing would take >250 years 
to identify all BRCA-carriers. Doubling current detection rates can identify all ‘detectable’ BRCA-
carriers in the general-population by year 2181, while parabolic and triple-linear rates can identify 
‘detectable’ BRCA-carriers by 2084 and 2093 respectively. The linear-fit model can identify 
‘detectable’ AJ carriers by 2044. We did not find an Angelina-Jolie effect on BRCA-carrier detection 
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rates. There was a significant difference in BRCA-detection rates between geographical regions over 
time (p<0.001).  
Conclusions 
The majority of BRCA-carriers have not been identified, missing key opportunities for 
prevention/earlier diagnosis. Enhanced and new strategies/approaches are needed.  
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Introduction 
Mutations in BRCA1/BRCA2 genes are associated with a high-risk of breast (BC) and ovarian cancer 
(OC) in women, as well as elevated risk of prostate and male-BC in men.[1, 2, 3] Identifying carriers is 
important because it offers the opportunity of early diagnosis and/or prevention to reduce the 
burden of BRCA-associated cancers in the population. Additionally, BRCA-carriers who develop 
cancer can be offered new targeted treatments such as PARP-inhibitors. For known mutation 
carriers there are a number of risk management options like preventive surgery for BC/OC,[4, 5] 
screening for BC,[6] chemoprevention with selective estrogen-receptor modulators,[7] lifestyle and 
reproductive advice incorporating breast feeding, contraception and opportunity to inform 
reproductive decision-making, including preimplantation genetic-diagnosis.[8, 9] The importance of 
prevention is magnified by the increasing costs of new drugs/treatment and persistent poor OC-
survival rates. Additionally the number of OC and BC cases are expected to rise by 27% and 24% 
respectively in the UK; and 55% and 55% respectively globally by 2035, leading to an increase in 
overall burden of disease.[10]  
Over the years health services have provided BRCA1/BRCA2 -testing using predominantly family-
history (FH) based clinical-criteria, with testing offered through specialised genetic services at 
BRCA1/BRCA2 mutation probability thresholds of initially 20% and subsequently this was reduced to 
a probability threshold of 10%.[11, 12] Several risk-models/clinical-criteria[13, 14, 15] are widely 
used to calculate these probabilities to identify individuals eligible for testing. This strategy is 
dependent on people and their doctors being aware of their FH and acting on it, accuracy of FH, 
communication within/between families and timely referrals to clinical genetics.  
To date the performance of a health-service in detecting BRCA1/BRCA2 mutations compared to the 
estimated prevalence for an entire population in a large geographical area has not been assessed. 
We report on the BRCA1/BRCA2 detection-rates across the entire Greater-London and bordering 
areas population since National-Health-Service (NHS) testing began from 1995-to-2014. We evaluate 
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the carrier identification rate across four geographical areas covered by NHS London regional 
genetic-services (RGS). We also for the first time forecast the time to pick up all identifiable 
BRCA1/BRCA2-carriers in the Greater-London and bordering areas population using current clinical 
protocols. These analyses are undertaken separately for both AJ and non-AJ general-populations.  
 
Methods 
Data on BRCA1/BRCA2-carriers identified by genetic-testing through the NHS London genetics 
laboratories between August-1993 and November-2014 were obtained from laboratory records and 
databases. This included date of test, carrier postcode, AJ-ethnicity (self-reported) and mutated 
gene (BRCA1/BRCA2).  
The first stage was to map the number of carriers identified in London by NHS providers over this 
period. In London, four NHS RGS and an independent NHS cancer-genetics centre provide clinical-
genetics care to a Greater-London and bordering areas population. Each of the four RGS covers a 
distinct area (A,B,C,D) comprising of a set of different postcode-sectors.[16] People are referred to 
the relevant RGS depending on their postal-address that falls in one of the postcode-sectors. The 
independent NHS genetics-centre received referrals from all four areas (A,B,C,D). We constructed 
the map of these four coverage areas (A,B,C,D) based on postcode-sectors, using ArcGIS 10.4 
software (Figure –1). Postcode-data of identified carries was matched to all known Greater-London 
and bordering areas postcodes in areas A,B,C,D. BRCA-carriers identified by the genetic laboratories 
from outside these four catchment-areas, were excluded from the analysis.  
These detection-rate data were compared to modelled estimates of the number of carriers in each 
area. Incorporating information from improved/contemporary sequencing technologies, updated 
mutation pathogenicity and modifications in penetrance, we recently estimated that BRCA1+BRCA2 
prevalence in the general-population to be 0.00677(CI:0.0059-0.0077).[17] These estimates are in 
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line with data from cancer-free women controls from the Australian Lifepool study.[18] Ashkenazi-
Jewish (AJ)-population data were obtained from our GCaPPS study which found BRCA-prevalence to 
be 0.0261(0.0173-0.0378).[19] A number of BRCA-carriers are missed by current clinical-criteria 
which are based on risk levels determined by FH. Recent estimates suggest only approximately 50% 
of general and 44% of AJ BRCA1/BRCA2-carriers[19] are ‘detectable’ using current clinical-genetics 
criteria. Population density data by boroughs and postcodes in the mapped Greater-London areas 
were obtained from the Office-for-National-Statistics (ONS) database. Data were obtained 
separately for both AJ and non-AJ general-populations. The Greater-London population served by 
the NHS RGS was estimated to be 16,696,608, of whom 190,997 are self-reported AJ (2011, ONS 
census).[20] Thus the detectable number of BRCA1/BRCA2 carriers in the general-population 
is=16505611*0.00677*0.5 [CI:16505611*(0.0059)*0.5; 16505611*(0.0077)*0.5]. The identifiable 
number of BRCA1/BRCA2 carriers in the AJ-population is=190997*0.0261*0.44 
[CI:190997*(0.0173)*0.44; 190997*(0.0378)*0.44]. 
To forecast the length of time from 2015 onwards it would take to detect all carriers using current 
clinical-criteria we first plotted detection curves of the number of carriers detected by time (Figure-
2). We then developed two different prediction models (Parabolic and Linear) in the general-&-AJ 
populations to fit the BRCA-carrier detection-rate data in the four geographical catchment-areas 
(A,B,C,D).  The first parabolic-model (equations below) fits the entire data set and reflects the 
dynamics of all carriers detected per year since testing began. However, detection rates appear 
constant for the last 6-8 years. The second linear-model (equations below)  is fitted only for part of 
the data where the detection-slope became close to constant, i.e. from year 2008 onwards for the 
general population and 2006 onwards for the AJ-population (Figures:2a,2b). The models were then 
used to predict time taken to identify all ‘detectable’ BRCA-carriers in the general-&-AJ populations 
from the year 2015 onwards. The modelling takes into account the change in population over time. 
We assume the population would change at the rate of change seen between 2001-2011 UK 
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census.[20, 21] Census data indicate the general-population would increase by 93,334/year and the 
AJ-population would decrease by 394/year across geographical areas A,B,C,D. 
For the general-population, parabolic-fit for total BRCA-carriers detected is 𝑦𝑦 = 277.67 − 124.76 ∗
𝑥𝑥 + 10.98 ∗ 𝑥𝑥2  (where 𝑥𝑥=1-year step from Jan-1993). While for the linear-fit, 𝑦𝑦 = 668.3 + 313.7 ∗
𝑥𝑥  (where 𝑥𝑥=1-year step from Jan-2008) curve provided best-fit for the data. For the AJ-population, 
the parabolic-fit was 𝑦𝑦 = 7.271 − 10.12 ∗ 𝑥𝑥 + 2.128 ∗ 𝑥𝑥2,   where 𝑥𝑥=1-year step from Jan-1996, 
while for the linear-fit, 𝑦𝑦 = 91.67 + 52.07 ∗ 𝑥𝑥 approximated the data best, where 𝑥𝑥=1-year step 
from Jan-2006. Figures-2a,2b show linear/parabolic function curves fitting the data. In addition to 
the linear-fit which reflects current detection-rate, the time taken with doubled and tripled 
detection-rates compared to the current linear-rate were also explored for general-&-AJ 
populations. Precise date-of-detection was missing for 163(5.5%) general-population carriers and 
these were excluded from model development. 
The relative detection-rates observed for people living across the four geographical-areas A,B,C,D 
(adjusted for total-population in each area) were compared over time. Mann-Whitney test was 
performed for the carriers detected in quarter-year windows, adjusted for the total-population in 
each of the four geographical-areas A,B,C,D. A sensitivity-analysis was also undertaken assuming 
missing RGS-status data from each genetic laboratory is distributed amongst the four areas in the 
same proportion as available data (Supplementary Table-S1).  
Angelina Jolie’s publicised decision to undergo a risk-reducing mastectomy created a media storm 
and public frenzy around BRCA-testing. We evaluated our data for an “Angelina Jolie” effect: change 
in detection-rate after she underwent risk-reducing mastectomy on 16.02.2013. 
Results 
Between 1993 and 2014 NHS genetic laboratories identified 3297 BRCA1/BRCA2 carriers in the 
general-population and 575 in the AJ-population. 27 AJ and 225 general-population BRCA-carriers 
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lived outside the RGS catchment areas and were excluded. Date of detection was available for 2916 
of 3072 general and 548 AJ carriers residing in Greater-London/bordering areas. Of these 
57%(1589/2798) general and 54%(266/491) AJ mutations were identified through cascade-testing 
(testing a known mutation in the family). Three general-population and six AJ-carriers had mutations 
in both BRCA1-&-BRCA2 genes. Overall 51%/62% BRCA1 and 49%/37% BRCA2 carriers belonged to 
general/AJ populations respectively.  The BRCA-carrier detection curves over time for general-&-AJ 
populations are given in Figure-2a, Figure-2b respectively. The estimated ‘total’ prevalence of BRCA-
carriers in Greater-London (areas:A,B,C,D)  is 111742(CI:97383,127093) in the general-population 
and 4985(CI:3304,7220) in the AJ-population. Of these the ‘detectable’ number using clinical-criteria 
is estimated as 55872(CI:48692,63547) in the general and 2193(CI:1454,3177) in the AJ-population 
respectively. The residual 55870 general and 2792 AJ carriers remain undetectable.  
Figure-1 shows a map of the Greater-London and bordering postcodes lying within the four 
geographical areas A,B,C,D. Table-1 provides the overall population and estimated carrier 
distribution across these four areas. Figure-3 and Figure-4 depict the forecasting models of the time-
to-detect the remaining BRCA-carriers from 2015 onwards for the general and AJ-populations 
respectively across the greater London-&-bordering areas. Each figure shows outcomes of linear and 
parabolic models and also where the linear-rate is doubled or tripled. Line-‘a’ reflects the total 
estimated carriers in the population and Line-‘c’ reflects the ‘detectable’ carriers.  ‘Line-a’–‘Line-c’ 
denotes the unidentifiable pool of BRCA-carriers using FH-based clinical-criteria. The current NHS 
detection-rate mirrors the linear function as the slope is near constant over the last 8years 
(Figures:2a,2b). Continuing at the current 2014 NHS detection-rate, will not be able to identify the 
‘detectable’ BRCA-carriers in the non-AJ general-population. Doubling these rates will enable 
identification of ‘detectable’ BRCA-carriers by the year 2181 (CI:2141,2228), while the parabolic and 
triple-linear rates can identify the ‘detectable’ BRCA-carriers in the population by 2084 
(CI:2077,2091) for parabolic or 2093 (CI:2077,2112) for tripled-linear rate. The current detection-
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rate for AJ-carriers will identify ‘detectable’ carriers by 2044 (CI:2032,2060), while doubling this 
linear-rate can do so by 2025 (CI:2019,2034).  
The detection-rates of BRCA-carriers over time across the four-areas A,B,C,D are plotted in 
Supplementary-Figures-S1a,S1b for general-&-AJ populations respectively. Corresponding RGS-area 
status information was missing for 22(4%) AJ and 675(23%) general-population BRCA-carriers. 
Hence, the analysis comparing rates across different areas A,B,C,D is limited to 96% AJ and 77% 
general-population carriers.  Comparisons of the mean-performance in quarter-year windows (as a 
ratio from all detectable carriers) are presented in Table-2. There was a significant difference in 
BRCA-carrier identification rates amongst people living across the four-areas A,B,C,D over time.  
Although we saw a numerical increase in the average quarter-year BRCA detection-rates in the 
18months after compared to 18months before “Angelina Jolie’s” mastectomy, this was not statistically 
significant for either the general (100 vs 85.7,p=0.059) or AJ populations (13 vs 12.8,p=0.612). 
Discussion 
We for the first time report on NHS BRCA-carrier identification-rates across the Greater-
London/bordering population over time. Over the years, only 2.6% of total estimated-carriers and 
5.1% of detectable-carriers have been identified in the general-population. Greater success has been 
achieved in the AJ-population with 10.9% of total-estimated and 24.9% of detectable AJ-carriers 
being identified. Nevertheless, the significantly large majority of BRCA-carriers at high-risk of cancer 
remain to be identified.  Although the parabolic-model has a steeper curve and quicker detection 
than the linear-model, the current detection-rates mirror a linear-slope far more rather than a 
parabolic one. Continuing at the 2014 identification-rate, the NHS is unable to identify the 
‘detectable’ pool of BRCA-carriers in the general-population, while it will take 30years to identify the 
‘detectable’ BRCA-carriers in the AJ-population. However, we expect the current detection rates to 
increase given the lowering of the BRCA1/BRCA2 probability threshold for genetic-testing to 10% in 
2013 and the recent introduction of mainstreaming of BRCA1/BRCA2 testing for OC-cases. The full 
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impact of this will emerge over the next few years and is therefore probably underestimated in our 
base case analysis. Nevertheless, even if the rate doubled it will take ~167 years to identify the 
detectable pool of BRCA-carriers and if it tripled it could still take 79years, with an exponential 
parabolic increase making it 70years to identify ‘detectable’ BRCA-carriers in the general-population. 
To expect a tripling or exponential increase is unrealistic. Most of the carriers who do not fulfil FH-
based clinical-testing criteria will however remain undetected. Various reasons for historic lower 
detection-rates include poor performance characteristics of clinical-criteria (limited sensitivity), less 
sensitive molecular tests, paternal inheritance, small family-size, incomplete penetrance, poor 
communication within/between families, population migration, poor physician/health-professional 
awareness, poor referral guideline implementation by non-genetic/primary-care clinicians, limited 
public awareness and population preferences.[19, 22] The rate-of-detection currently being 
achieved is not adequate to maximise BRCA-carrier identification for cancer screening and 
prevention.  
 
Around 10% epithelial-OC[23] (84% of OC)[24] and 9.8% triple-negative(TN) BC[25] (13.5% of BC)[25] 
unselected for FH have BRCA-mutations. Testing is now advocated in them from 2015 in the UK.[26] 
This approach will also enable identification of BRCA-carriers lacking a strong FH. Our study population 
comprises 26.4% of the UK population.[20] Assuming proportionate UK annual OC-&-BC incidence in 
our population (OC-incidence=0.264*7400; TNBC-incidence=0.264*55200)[27, 28] and two additional 
carriers identified from cascade testing[29] for each index-case, we incorporated the additional  
impact of testing all epithelial-OC and TNBC in the models to detect ‘total’ BRCA-carriers in the 
population. Addition of testing epithelial-OC/TNBC at cancer diagnosis to current detection-rates, will 
take >250years (2286) to identify the ‘total’ BRCA-carriers in the general-population. Coupled with the 
doubled-linear fit, tripled-linear fit and parabolic-fit, ‘total’ BRCA-carriers could be detected by 2226, 
2181, and 2128 respectively. Hence, even if ‘everyone’ is tested at cancer diagnosis, it will take an 
inordinately long time to identify all at-risk BRCA-carriers.  
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Our study has a number of advantages. We incorporate data since NHS BRCA-testing began. We use 
most recent estimates of BRCA1/BRCA2 mutation frequencies for the AJ[19]  and general-
populations,[17] and incorporate the potential change in population size over time. Limitations 
include exclusion of any BRCA-testing in the private sector. Unfortunately these data are 
unavailable/inaccessible. However, most BRCA-testing in the UK health-system is undertaken 
through the NHS. The private health-sector is miniscule compared to the public NHS. According to 
the King’s fund only ~11% of UK-residents have some private medical insurance. However, that does 
not equate to 11% of BRCA-testing being done privately and the proportion of private BRCA-testing 
is probably much lower. A sensitivity-analysis assuming 11% additional BRCA-carriers identified 
through other sources indicates that doubling or tripling the linear-model would detect general-
population carriers by 2146(CI:2116,2185), or 2080(CI:2067-2095) respectively. Additionally all 
identifiable AJ BRCA-carriers could be detected by 2040(CI:2029-2055). This does not majorly shift 
the time-to-detection estimates predicted using our models. We cannot account for predictive-
testing undertaken by family members living outside London. However, the analysis incorporates 
cascade-testing of London-based individuals whose familial mutation may have been diagnosed 
outside London. Unlike some reports we did not find an ‘Angelina Jolie’ effect translating to a higher 
carrier detection-rate.[30] Nevertheless, this is consistent with other findings of increased genetic-
testing referrals from the worried well, with many not fulfilling testing criteria.[31]  
 
Our analysis is not limited/restricted by age of testing. Our data set had anonymised data without 
date of birth or age distribution of carriers. This may be considered as a limitation by others. 
However, predictive pre-symptomatic testing for BRCA mutations is currently offered in the UK from 
the age of autonomous consent i.e. 18 years.[32, 33, 34] This is consistent with many international 
guidelines.[35, 36, 37, 38, 39] This is a time series analysis spanning up to 250 years in the prediction 
models. Within 18 years’ time someone who is <1 year old will become eligible for testing. Limiting 
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testing to say ≥30 years in our view is a paternalistic approach. Potential clinical benefits for testing 
between the ages of 18 and 30 years include, the opportunity to make contraceptive, lifestyle and 
reproductive choices including PGD that can minimise risk. Earlier awareness can help decision 
making in some women who may choose to complete their families earlier so as to have timely 
surgical prevention later. Taking the pill at younger ages (rather than >30), at a lower absolute risk of 
breast cancer will have a lower detrimental impact on breast cancer risk while providing the benefit 
of ovarian cancer risk reduction. Experience from clinical practice as well as our population testing 
research trials support and show acceptability of genetic testing from 18 years.[19, 40, 41] There is 
no upper age limit for BRCA testing in the UK. The annualised risk of developing ovarian cancer is 
~1% per annum in the older age group. The average life expectancy in women is ~85 years, and 
statistically this is even greater in older women. Hence the residual risk is still high enough to offer 
surgical prevention and many older women >70-75 years attending our clinics opt for this. 40% of 
ovarian cancers occur in the >70 age group and 28% in the >75 years age group.[42] BRCA carrier 
identification even in older women offers the opportunity for predictive/cascade testing for other 
unaffected family members with implications for screening/prevention and cancer risk-reduction. 
Additionally this has implications for their care with respect to improving survival through use of 
drugs like PARP inhibitors. Hence, for these reasons we feel the analysis should not be restricted by 
age.  
 
Our data show regional differences in identification of BRCA-carriers across London. Identification-
rates were higher amongst AJ and general-population people living in C-&-D postcode-sectors than 
those within areas A-&-B. A limitation of the analysis is incomplete RGS data for 23% general-
population carriers. However, a sensitivity-analysis assuming proportionate attribution of RGS to 
these 23% carriers detected does not change the variation in carrier identification rates observed 
between different London regions (Supplementary-Table-S1, Figures-S2,S3). The precise reasons for 
why apparently more people living in areas C-&-D come forward for testing compared to areas A-&-
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B cannot be evaluated through this analysis and require further study. We had access to limited 
anonymised data and lacked broader individual carrier-level variables/factors to properly analyse 
socio-economic or population factors affecting testing uptake across different areas. We also lacked 
information on total number of BRCA-tests undertaken (including those testing negative). There are 
socio-economic differences in populations across different London areas. The Index-of-Multiple-
Deprivation (IMD) incorporates seven domains to produce an official measure for relative 
deprivation across small areas. The majority of the London areas present amongst the 20% most 
deprived in the country are represented across area-A postcodes, followed by area-B and then area-
C. The least deprived being in area-D postcodes.[43] Differences in population characteristics, socio-
economic status, knowledge, awareness, population attitudes itself may contribute to this disparity 
observed in testing and detection-rates. Additional contributory factors include NHS structural 
changes with genetic-clinics in some areas being established a few years after others and in part 
oncology services through which the affected proband carrying the familial mutation is ascertained.  
There is limited awareness of BRCA testing amongst clinicians/practitioners and the population per 
se. Low referral rates for genetic counselling and subsequent BRCA testing have been reported by 
others too, which further highlights the missed therapeutic and prevention opportunities.[44] 
Understanding reasons for differences observed is important and requires further research. This can 
help plan interventions to address underlying issues and improve carrier identification.  
 
The number of OC/BC cases are predicted to rise by 27%/24% respectively in the UK; and 55%/55% 
respectively globally, over the next 20years.[10] BRCA-carriers have a 17-44% OC-risk and 69%-71% 
BC-risk by 80-years.[1, 2] Uptake of screening and prevention options is cost-effective in reducing 
BC-&-OC incidence.[45, 46] Hence, BRCA-carrier identification driven precision-medicine and cancer 
prevention provides an excellent opportunity to reduce future cancer burden and improve health 
outcomes, the importance of which is magnified by current economic/funding constraints (2.4% NHS 
budgetary shortfall).[47]  
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The limited Greater-London BRCA detection rates achieved and long predicted time-to-identification 
observed highlights a need for change. We postulate that a similar situation probably exists across 
many other parts of the UK, Europe and other Western countries. Concerted efforts are required to 
increase knowledge and awareness amongst health-professionals (hospital specialists and primary-
care general practitioners) the general public regarding current access, guidelines and health-system 
pathways for BRCA-testing. Additional steps are needed to simplify access and expand availability of 
BRCA-testing, including, investment in genetics infrastructure/services, relaxing current clinical-
testing thresholds, as well as implementing new ascertainment strategies like testing at cancer 
diagnosis.  
 
Systematic population-based testing has been advocated as one key innovative strategy. Population-
testing can identify the large pool of carriers who remain undetected using FH-based approaches. It 
would also provide a strong stimulus to push carrier detection-rates to higher levels compared to 
current trends, providing a greater impetus for earlier identification and consequent OC/BC 
prevention. Next-generation-sequencing technologies and advanced bioinformatics now enable 
population-testing. In the AJ-population this has been, and found to be acceptable, safe, effective and 
cost-saving.[19, 22, 48, 49, 50] While population-testing should be implemented in the AJ-population, 
further research is needed before implementation in the general non-AJ population.  A pilot-study is 
underway in the UK.[41] We recently showed that such an approach of population based genetic 
testing would be cost-effective in the general non-Jewish population too.[51] We call for research 
studies to understand the overall impact, and evaluate delivery mechanisms and pathways for a 
population-based BRCA-testing strategy in the general-population.  
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Table-1: Population and estimated BRCA carrier distribution by four London areas A, B, C, D 
 
London 
Area 
Total 
General 
Population 
Total AJ 
Population 
Total 
Estimated 
BRCA 
carriers 
General 
Population 
Total 
estimated 
BRCA 
carriers AJ 
Population 
Detectable 
BRCA 
carriers 
General 
Population 
Detectable 
BRCA 
carriers AJ 
Population 
A 4545545 60135 30773 1570 15387 691 
B 4467689 110796 30246 2892 15123 1272 
C 3825404 9170 25898 239 12949 105 
D 3666973 10896 24825 284 12413 125 
TOTAL 16505611 190997 111742 4985 55872 2193 
 
AJ- Ashkenazi Jewish 
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Table-2: Comparison of BRCA identification rates across four London areas A, B, C, D 
  
General Population 
London Area  A B C D 
 Means 0.00051 0.00083 0.00115 0.00183 
A 0.00051  p<0.001 p<0.001 p<0.001 
B 0.00083   p=0.014 p<0.001 
C 0.00115    p<0.001 
D 0.00183     
Jewish Population 
London Area  A B C D 
 Means 0.0053 0.0038 0.0243 0.0122 
A 0.0053  p=0.078 p<0.001 P=0.003 
B 0.0038   p<0.001 p<0.001 
C 0.0243    p<0.001 
D 0.0122     
 
Table-2 compares mean slope of carriers detected in quarter-year windows, adjusted for the total 
BRCA carriers in the population living in the four different London areas. P values of Mann Whitney 
tests are given in the different cells. The top half of the table reflects data for the general population 
and the bottom half data for the Jewish population. 
For the general population BRCA detection seen within people living in Area D > Area C > Area B > 
Area A.  
For the AJ population BRCA detection seen within people living in Area C > Area D > Area B or A 
(Table-2). 
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Figure 1: Map of London coverage areas (A, B, C, D) 
Greater London post code areas A, B, C, D covered in the analysis 
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Figure 2: Number of carriers identified by time in the General and Ashkenazi Jewish populations in 
London and greater London 
 
Figure 2a: Number of carriers identified by time in the general population in London and greater 
London. The figure shows the fit of Linear and Parabolic curves to the BRCA carrier detection rate 
data in general population. X axis: Number of carriers detected. Y axis: Date of detection. 
 
Figure 2b: Number of carriers identified by time in the Ashkenazi Jewish population in London and 
greater London. The figure shows the fit of Linear and Parabolic curves to the BRCA carrier detection 
rate data in the Ashkenazi Jewish population. X axis: Number of carriers detected. Y axis: Date of 
detection. 
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Figure 3: Time to detection from 2015 onwards for the remaining estimated BRCA carriers in the 
general population across London and greater London. 
 
Figure-3 shows the predicted time to detection outcomes of parabolic, linear, double linear and 
triple linear prediction models for BRCA carriers in the general population. Line a- reflects the total 
estimated carriers in the population. Line c- reflects the detectable carriers. Lines b and d are the 
upper and lower confidence limits for Line c. Line ‘a – c’ reflects the unidentifiable pool of carriers 
using FH based clinical criteria.  
The detectable BRCA carriers in the general population cannot be identified by the linear model. A 
double linear rates will enable identification of ‘detectable’ BRCA-carriers by the year 2181 (CI:2141, 
2228). The parabolic and triple linear rates will identify the ‘detectable’ BRCA-carriers in the 
population within 100 years. This will occur by the year will be 2084 (CI: 2077, 2091) with the 
parabolic or year 2093 (CI: 2077, 2112) with the tripled linear rate model. 
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Figure 4: Time to detection from 2015 onwards for the remaining estimated BRCA carriers in the 
Ashkenazi Jewish population across London and greater London. 
 
Figure-4 shows the predicted time to detection outcomes of parabolic, linear, double linear and 
triple linear prediction models for BRCA carriers in the Ashkenazi Jewish (AJ) population. Line a- 
reflects the total estimated carriers in the AJ population. Line c- reflects the detectable carriers. 
Lines b and d are the upper and lower confidence limits for Line c. Line ‘a – c’ reflects the 
unidentifiable pool of carriers using family history based clinical criteria.  
The linear fit model can identify detectable carriers by the year 2044 (CI: 2032-2060). The doubled 
linear rat model can do so by year 2025 (CI: 2019-2034), and tripling it could do so by year 2019 (CI: 
2014-2025). The Parabolic model could potentially detect the detectable carriers by year 2030 (CI: 
2025-2037). 
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